Advertisement

Subcutaneous Treprostinil Improves Surgical Candidacy for Next Stage Palliation in Single Ventricle Patients With High-Risk Hemodynamics

      Single ventricle (SV) patients with pulmonary vascular disease (SV-PVD) are considered poor surgical candidates for Glenn or Fontan palliation. Given limited options for Stage 1 (S1) and Stage 2 (S2) SV patients with SV-PVD, we report on the use of subcutaneous treprostinil (TRE) to treat SV-PVD in this population. This single-center, retrospective cohort study examined SV patients who were not candidates for subsequent surgical palliation due to SV-PVD and were treated with TRE. The primary outcome was ability to progress to the next surgical stage; secondary outcomes included changes in hemodynamics after TRE initiation. Between 3/2014 and 8/2021, 17 SV patients received TRE for SV-PVD: 11 after S1 and 6 after S2 (median PVR 4.1 [IQR 3.2–4.8] WU*m2 and 5.0 [IQR 1.5–6.1] WU*m2, respectively). Nine of 11 (82%) S1 progressed to S2, and 2 (18%) underwent heart transplant (HTx). Three of 6 (50%) S2 progressed to Fontan, 1 underwent HTx and 2 are awaiting Fontan on TRE. TRE significantly decreased PVR in S1 patients with median post-treatment PVR of 2.0 (IQR 1.5–2.6) WU*m2. TRE can allow for further surgical palliation in select pre-Fontan patients with SV-PVD, obviating the need for HTx. Improvement in PVR was significant in S1 patients and persisted beyond discontinuation of therapy for most patients.

      Graphical abstract

      Keywords

      Abbreviations:

      mPAP (mean pulmonary artery pressure), SV-PVD (single ventricle patients with pulmonary vascular disease), PVR (indexed pulmonary vascular resistance), Qp (pulmonary blood flow), S1 (stage 1 (shunt dependent pulmonary blood flow)), S2 (stage 2 (superior cavopulmonary anastomosis)), SpO2 (systemic oxygen saturation), SV (single ventricle), TPG (transpulmonary gradient), TRE (treprostinil)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gewillig M
        • Brown SC
        • Bruaene A
        • et al.
        Providing a framework of principles for conceptualising the Fontan circulation.
        Acta Paediatr. 2020; 109: 651-658https://doi.org/10.1111/apa.15098
        • Choussat A
        • Fontan F
        • Besse P
        Selection criteria for the Fontan procedure.
        in: Anderson R Shinebourne E Paediatric Cardiology: Churchill Livingstone. 1977
        • Stern HJ
        Fontan “Ten Commandments” revisited and revised.
        Pediatr Cardiol. 2010; 31: 1131-1134https://doi.org/10.1007/s00246-010-9811-9
        • Colquitt JL
        • Morris SA
        • Denfield SW
        • et al.
        Survival in children with down syndrome undergoing single-ventricle palliation.
        Ann Thorac Surg. 2016; 101: 1834-1841https://doi.org/10.1016/j.athoracsur.2015.11.047
        • Malhotra SP
        • Ivy DD
        • Mitchell MB
        • et al.
        Performance of cavopulmonary palliation at elevated altitude: midterm outcomes and risk factors for failure.
        Circulation. 2008; 118https://doi.org/10.1161/CIRCULATIONAHA.107.751784
        • Alsoufi B
        • Manlhiot C
        • Awan A
        • et al.
        Current outcomes of the Glenn bidirectional cavopulmonary connection for single ventricle palliation.
        Eur J Cardiothorac Surg. 2012; 42: 42-49https://doi.org/10.1093/ejcts/ezr280
        • Handler SS
        • Ogawa MT
        • Hopper RK
        • et al.
        Subcutaneous treprostinil in pediatric patients with failing single-ventricle physiology.
        J Heart Lung Transplant. 2018; 37: 306-307https://doi.org/10.1016/j.healun.2017.09.008
        • Chen X
        • Cai XM
        • Zhang MJ
        • et al.
        Pharmacokinetics of treprostinil in children with functional single-ventricle pulmonary arterial hypertension: a randomized controlled trial.
        Ann Transl Med. 2021; 9: 1163https://doi.org/10.21037/atm-21-3188
        • Driscoll DJ
        • Offord KP
        • Feldt RH
        • et al.
        Five- to fifteen-year follow-up after Fontan operation.
        Circulation. 1992; 85: 469-496https://doi.org/10.1161/01.CIR.85.2.469
        • Kaulitz R
        • Ziemer G
        • Luhmer I
        • et al.
        Modified fontan operation in functionally univentricular hearts: Preoperative risk factors and intermediate results.
        J Thorac Cardiovasc Surg. 1996; 112: 658-664https://doi.org/10.1016/S0022-5223(96)70049-1
        • Knott-Craig C
        • Danielson G
        • Schaff H
        • et al.
        The modified fontan operation: an analysis of risk factors for early postoperative death or takedown in 702 consecutive patients from one institution.
        J Thorac Cardiovasc Surg. 1995; 109: 1237-1243
        • Burkhart HM
        • Dearani JA
        • Mair DD
        • et al.
        The modified fontan procedure: early and late results in 132 adult patients.
        J Thorac Cardiovasc Surg. 2003; 125: 1252-1258https://doi.org/10.1016/S0022-5223(03)00117-X
        • Lévy M
        • Danel C
        • Laval AM
        • et al.
        Israël-Biet D. Nitric oxide synthase expression by pulmonary arteries: A predictive marker of Fontan procedure outcome?.
        J Thorac Cardiovasc Surg. 2003; 125: 1083-1090https://doi.org/10.1067/mtc.2003.193
        • Ishida H
        • Kogaki S
        • Ichimori H
        • et al.
        Overexpression of endothelin-1 and endothelin receptors in the pulmonary arteries of failed Fontan patients.
        Int J Cardiol. 2012; 159: 34-39https://doi.org/10.1016/j.ijcard.2011.02.021
        • Ridderbos FJS
        • Wolff D
        • Timmer A
        • et al.
        Adverse pulmonary vascular remodeling in the Fontan circulation.
        J Heart Lung Transplant. 2015; 34: 404-413https://doi.org/10.1016/j.healun.2015.01.005
        • Giardini A
        Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients: reply.
        Eur Heart J. 2008; 30: 508https://doi.org/10.1093/eurheartj/ehp036
        • Goldberg DJ
        • French B
        • McBride MG
        • et al.
        Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial.
        Circulation. 2011; 123: 1185-1193https://doi.org/10.1161/CIRCULATIONAHA.110.981746
        • Goldberg DJ
        • Zak V
        • Goldstein BH
        • et al.
        Results of the FUEL Trial.
        Circulation. 2020; 141: 641-651https://doi.org/10.1161/CIRCULATIONAHA.119.044352
        • Hebert A
        • Mikkelsen UR
        • Thilen U
        • et al.
        Bosentan improves exercise capacity in adolescents and adults after fontan operation: the tempo (treatment with endothelin receptor antagonist in fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study.
        Circulation. 2014; 130: 2021-2030https://doi.org/10.1161/CIRCULATIONAHA.113.008441
        • Derk G
        • Houser L
        • Miner P
        • et al.
        Efficacy of endothelin blockade in adults with fontan physiology.
        Congenital Heart Dis. 2015; 10: E11-E16
        • Cedars AM
        • Saef J
        • Peterson LR
        • et al.
        Effect of Ambrisentan on Exercise Capacity in Adult Patients After the Fontan Procedure.
        Am J Cardiol. 2016; 117: 1524-1532https://doi.org/10.1016/j.amjcard.2016.02.024
        • Khajali Z
        • Peighambari M
        • Lotfian S
        • et al.
        Tadalafil and exercise capacity after fontan operation.
        Res Cardiovasc Med. 2018; 7: 64https://doi.org/10.4103/rcm.rcm_18_17
        • Mori H
        • Park IS
        • Yamagishi H
        • et al.
        Sildenafil reduces pulmonary vascular resistance in single ventricular physiology.
        Int J Cardiol. 2016; 221: 122-127https://doi.org/10.1016/j.ijcard.2016.06.322
        • Jeremiasen I
        • Tran-Lundmark K
        • Idris N
        • et al.
        Pulmonary vasodilator therapy in children with single ventricle physiology: effects on saturation and pulmonary arterial pressure.
        Pediatr Cardiol. 2020; (Published online July 30)https://doi.org/10.1007/s00246-020-02424-w
        • Abman SH
        • Hansmann G
        • Archer SL
        • et al.
        Pediatric pulmonary hypertension: guidelines from the american heart association and american thoracic society.
        Circulation. 2015; 132: 2037-2099https://doi.org/10.1161/CIR.0000000000000329
        • Rosenzweig EB
        • Abman SH
        • Adatia I
        • et al.
        Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.
        Eur Respir J. 2019; 531801916https://doi.org/10.1183/13993003.01916-2018
        • Barst RJ
        • Maislin G
        • Fishman AP
        Vasodilator therapy for primary pulmonary hypertension in children.
        Circulation. 1999; 99: 1197-1208https://doi.org/10.1161/01.CIR.99.9.1197
        • Siehr SL
        • Ivy DD
        • Miller-Reed K
        • et al.
        Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics.
        J Heart Lung Transplant. 2013; 32: 546-552https://doi.org/10.1016/j.healun.2013.01.1055
        • Hollander SA
        • Ogawa MT
        • Hopper RK
        • et al.
        Treprostinil improves hemodynamics and symptoms in children with mild pulmonary hypertension awaiting heart transplantation.
        Pediatr Transplant. 2020; 24: e13742https://doi.org/10.1111/petr.13742
        • Levy M
        • Del Cerro MJ
        • Nadaud S
        • et al.
        Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension.
        Int J Cardiol. 2018; 264: 153-157https://doi.org/10.1016/j.ijcard.2018.03.067
        • McIntyre CM
        • Hanna BD
        • Rintoul N
        • et al.
        Safety of epoprostenol and treprostinil in children less than 12 months of age.
        Pulm Circ. 2013; 3: 862-869https://doi.org/10.1086/674762

      Linked Article